



1601(9E17)

p#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Friedhelm BLUME et al.

Serial No.: 09/988,008

Group Art Unit: 1642

Filed: November 16, 2001

Examiner: Not assigned

For: USE OF ENDOTHELIN CONJUGATES IN THERAPY, NEW ENDOTHELIN CONJUGATES, AGENTS THAT CONTAIN THE LATTER, AND PROCESS FOR THEIR PRODUCTION

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents  
Washington, D. C. 20231

RECEIVED

APR 11 2002

TECH CENTER 1600/2900

Sir:

CITED MATERIALS

Applicant(s) hereby disclose the information listed in the attached form PTO-1449.

- ☒ Copies of materials listed but not attached were cited in parent application Serial No. 09/319,414; see 37 C.F.R. § 1.98(d).
- ☐ Copies of materials listed but not attached were cited in an International Search Report dated \_\_\_\_; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed \_\_\_\_.

ADDITIONAL INFORMATION

[NONE?]

LANGUAGE

- ☒ All listed materials are in the English language; see 37 C.F.R. § 1.98.
- ☐ Non-English language references:
  - ☐ The reference(s): \_\_\_\_\_ in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): \_\_\_\_\_, respectively.
  - ☐ (An) English-language translation(s) of the references: \_\_\_\_\_ is (are) provided.
  - ☐ A commercial English-language abstract of reference(s) \_\_\_\_\_ is (are) provided.
  - ☐ An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a

counterpart foreign application, is provided indicating the relevance of the cited reference(s).

### FEES

- ☒ No fee is required for this Information Disclosure Statement because:
  - ☐ This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
  - ☒ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
  - ☐ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
  - ☐ This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
- ☐ A fee is required for this Information Disclosure Statement:
  - ☐ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in § 1.17(p).
  - ☐ This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.

### CERTIFICATION

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$\_\_\_\_\_. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



---

Robert E. McCarthy, Reg. No. 46,044  
Agent for Applicants

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1  
2200 Clarendon Blvd. Suite 1400  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1699-C1

Date: April 9, 2002  
REM:jmj

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DKT. NO. SCH 1699C1	SERIAL NO. 09/988,008
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>APPLICANT</b> Ludger DINKELBURG et al.	
		<b>FILING DATE</b> 12-10-99	<b>GROUP</b> 1614

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
AA	5260276	11-9-93	Cody et al.			
AB	5616608	4-1-97	Kinsella et al.			
AC	5639860	6-17-97	Tanaka et al.			
AD	5631222	5-20-97	Shibita et al.			
AE	5688499	11-18-97	Banting et al.			
AF	5352659	10-4-94	Wakimasu et al.			
AG	5637113	6-10-97	Tartaglia et al.			
AH						
AI						
AJ						
AK						
AL						

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
AM	9602568	2-1-96	WO				
AN	2194294	2-1-96	CA				
AO	4301871	7-14-94	DE				
AP	2113245	7-14-94	CA				
AQ	4428851	2-08-96	DE				
AR	2195318	2-15-96	CA				
AS	9712850	4-10-97	WO				
AT	2232620	4-10-97	CA				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	<b>AU</b>	Boulanger C.M. et al.: "Hirudin and nitrates inhibit the thrombin-induced release of endothelin from the intact porcine aorta" CIRC.RES., 1991, vol 68, no.6, pp.1768-1772
	<b>AV</b>	Yang et al: "17 beta-Oestradiol inhibits growth of human vascular smooth muscle: similar effects in cells from female and males" JOURNAL OF CARDIOVASCULAR PHARM. April 1996, vol.28 supp.5,pp.S34-s39
	<b>AW</b>	Luscher TF et al. "Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle." DRUGS, 1993, Vol. 46 suppl 2, pp. 121-132
	<b>AX</b>	Achmad T.H et al. "Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers" BIOCHEM BIOPHYS. RES. COMM ,1992 Vol.189 No2 pp 994-1000
	<b>AY</b>	Barry W.L et al: "Antiplatelet and anticoagulant therapy in patients undergoing percutaneous transluminal coronary angioplasty" CARDIOL. CLIN., 1994 Vol. 12. No. 3 pp.517-535
	<b>AZ</b>	Laurent S. et al." La Paroi Arterielle: Une Nouvelle cible Pharmacologique et Therapeutique?" THERAPIE, 1995 Vol. 50 no 4, pp.387-398
<b>Examiner</b>		<b>Date Considered</b>

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**SERIAL NO.**  
09/988,008

**APPLICANT**  
Dinkelburg et al.

**FILING DATE**  
11-26-99

**GROUP**  
1614

[illegible]

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	BA	9710853	3-27-1997	WO				
	BB	2232340	3-27-97	CA				
	BC	9219644	11-12-92	WO				
	BD	9503795	2-9-95	WO				
	BE	9321945	11-11-93	WO				
	BF	4337599	5-4-95	DE				
	BG	9422491	10-13-94	WO				
	BH	2156618	10-13-94	CA				

	<b>BI</b>	Derwent English language Abstract of EP 548441

**Date Considered**

APR 09 2002

APR 09 2002

APR 09 2002

APR 09 2002

APR 09 2002

APR 09 2002

APR 09 2002

		Molenaar et al., "Characterization of two new ETB selective radioligands in human heart", Br. J Pharmacology, Vol. 107, pp. 637-639. (Abstract)
<b>Examiner</b>		<b>Date Considered</b>